Background: The aim of this work was to evaluate the influence of UPOINT-guided (Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, Tenderness of skeletal muscles) multimodal therapy in patients with chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) on the dynamic values of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score. Patients and methods: In our study we investigated 110 patients aged 26–68 years with CP/CPPS. We performed digital rectal examination (DRE), pre- and post-massage test (PPMT) urine culture, urine analysis, transrectal ultrasound investigation of prostate, antibiotic susceptibility testing. We divided the patients into the intervention group and the control group which was followed up without any therapy. For the intervention group we offered multimodal therapy based on each predominated positive phenotype. For the urinary phenotype, patients in intervention group received 10 mg alfuzosin. For organ-specific and tenderness domains, the patients of the intervention group received 63 mg Cernilton and 1 g Quercetin. For infection control, the patients of the intervention group received antimicrobial agents according to the results of the post-massage urine culture, antibiotic susceptibility testing and a high level of contamination >105 colony-forming units (CFU)/ml. Microbiological assessment of PPMT urine culture was conducted with aerobic and anaerobic methods of cultivation Results: The 110 patients had an average age of 43.9 ± 11.1 years and a median duration of symptoms of 6.21 ± 1.8 months. Of these, 11 patients did not complete the trial and therefore in quantitative terms, the distribution of patients was as follows: 54 in the intervention group and 45 in the control group. The average total NIH-CPSI score before treatment was 29.8 ± 6.1 in both groups. The mean NIH-CPSI of the pain, urinary, and quality of life (QOL) subscores before treatment was 15.1 ± 3.0, 7.4 ± 1.4 and 8.1 ± 2.1, respectively in both groups. After 6 weeks the PPMT urine culture of patients of the intervention group showed the absence or low-level contamination of microorganisms. After conducting the treatment, the mean total NIH-CPSI score in the intervention and control groups was 13.9 ± 2.8 ( p = 0.025) and 29.8 ± 5.8 ( p = 0.18), respectively. The average NIH-CPSI pain subscore in the intervention and control group after treatment was 6.7 ± 1.4 ( p = 0.018) and 15.1 ± 2.8 ( p = 0.21), respectively. The mean NIH-CPSI urinary subscore after treatment in the intervention and control group was 3.22 ± 1.07 ( p = 0.045) and 7.4 ± 1.2 ( p = 0.15), respectively. The average NIH-CPSI QOL subscore after treatment in the intervention and control group was 3.87 ± 1.28 ( p = 0.015) and 8.1 ± 1.9 ( p = 0.35). After multimodal therapy, the prevalence of different UPOINT-positive domains in the patients of both intervention groups did not exceed 14%. Conclusions: The UPOINT clinical phenotypes significantly changed after multimodal treatment, including antibiotics, phytotherapy and α-blockers in patients with CP/CPPS. This combination of treatment showed a decreasing total NIH-CPSI score and an elevation of QOL in patients.

No abstract

Residual penile curvature is a common situation following the implantation of a penile prosthesis in patients with Peyronie's disease. Currently, there is a variety of options for the correction of residual curvature, including penile modeling, plication techniques, as well as tunical incision/excision with or without grafting. A literature search of PubMed and Medline databases was conducted from 1964 until 2020, using search terms for all articles in the English language. In this article, we provide a review of the techniques and the outcomes, according to the published literature.

Currently, therapeutic interventions for erectile dysfunction in chronic prostatitis encounter a number of obstacles due to the lack of system-structural approach to sex pathological syndromes so new possibilities of correction of sexual disorders should be explored adequately influencing all the hierarchical levels to ensure the copulatory cycle. The aim of the study is a pathogenetic substantiation of the system magnetic therapy in treatment of patients with chronic prostatitis with erectile dysfunction. Materials and methods. Monitoring of 40 patients with chronic prostatitis with erectile dysfunction aged 22 to 45 years was carried out. All patients taking physical therapy, prostate massage, psychotherapy correction of sexual maladjustment had a course of system magnetic therapy on Magnitoturbotron «EOL» in the «Standard» mode, the rotational speed of the magnetic field of 100 Hz in 1 Hz steps, the direction of rotation of the magnetic field was direct, clockwise, the maximum value of the magnetic field - 1.5-2.0 mT for 15 minutes a day in an amount of 15 procedures. Results. Application of the system of magnetic therapy for chronic prostatitis with erectile dysfunction has a direct effect on the prostate, helping to reduce edema, leukocyte infiltration and glands venules thrombosis and has antiplatelet activity, improving peripheral blood circulation and lymph flow, on the other hand, it increases the duration of erections, improves psychophysical and emotional state. The result is a normalization of the frequency of regular coitus, with the final phase of ejaculation, an improvement of mental and physical and emotional health, which is fundamental in terms of pathogenetic therapy of CP with erectile dysfunction. In addition surveys’ matrix correlation analysis carried out on a scale IIEF showed a clear relationship of the life quality improvement and the disappearance or significant decrease in the severity of pain, increased duration of erection and improvement of the functional status of the prostate.